Daxor Corporation logo

Daxor Corporation(DXR)

upturn advisory logo
ADVISORIES YOU CAN VERIFY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 6 days
PROFIT SINCE LAST BUY
-0.17%
LAST CLOSE
$11.45
09/18/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close

Advisory Performance History (Simulated)Advisory Performance History info

Upturn Advisory & Investor View for DXR

09/18/2026: DXR (1-star) has a low Upturn Star Rating. Not recommended to BUY.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit -31.49%
Avg. Invested days 29
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 09/18/2026

Upturn Scorecard

Upturn Star Rating

DXR receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

DXR has moderate overall fundamentals (3 stars), with solid financial health, moderate growth momentum, and moderate ownership. In FY2025 versus FY2024, strong earnings growth (+1609.7%) and strong profitability (net margin 1821.5%) are partially offset by soft cash generation (FCF margin -120.1%), negative revenue growth (-76.4%).

Financial Health Rating

DXR's financial health is supported by strong profitability, including gross margin of 37.5% and operating margin of 1824.7%. Liquidity is soft (2 stars), which helps explain the 4-star overall score.

Growth Momentum Score

Earnings growth is DXR's strongest growth driver at +1609.7% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (-76.4%, negative) and free-cash-flow growth (-2452.6%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

Institutional ownership is 7.0% and approximately 49.7% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 49.50% supports management-shareholder alignment.

Top 5 Institutional Investors

Thompson, Siegel & Walmsley LLC 4.14%
Vanguard Capital Management, LLC 0.83%
Aristides Capital LLC 0.71%
Renaissance Technologies Corp 0.48%
Susquehanna International Group, LLP 0.24%

Unit Economics (Per $1K Revenue)

DXR generates approximately $375 of gross profit, $18,247 of operating income, and $-1,201 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong margins, cash conversion, and capital efficiency support the rating.

Economic Dimensions

Effective Tax Rate: 0.00%

Quantitative Style Profile

DXR has a relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap Risk

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 66.85M USD
Price to earnings Ratio 6.78
1Y Target Price 20
Price to earnings Ratio 6.78
1Y Target Price 20
Volume (30-day avg) 27.9K shares
Beta 0.26
52 Weeks Range 8.56 - 14.76
Updated Date 09/20/2026
52 Weeks Range 8.56 - 14.76
Updated Date 09/20/2026
Dividends yield (FY) -
Basic EPS (TTM) 1.69
Advertisement

Valuation

Trailing PE 6.78
Forward PE 64.52
Enterprise Value 42.93M
Price to Sales(TTM) 2131.62
Enterprise Value 42.93M
Price to Sales(TTM) 2131.62
Enterprise Value to Revenue 8.2
Enterprise Value to EBITDA -
Shares Outstanding 5.84M
Shares Floating 2.90M
Shares Outstanding 5.84M
Shares Floating 2.90M
Percent Insiders 49.5
Percent Institutions 7.02

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

About Daxor Corporation

Exchange NASDAQ
Headquarters Oak Ridge, TN, United States
IPO Launch date 1992-03-17
Chairman, President & CEO Mr. Michael Richard Feldschuh
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees -
Full time employees -

Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.